CompletedNCT00924326Updated Jan 12, 2022Results posted

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

A Phase 1/2 interventional study of Fludarabine and Cyclophosphamide in Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma and Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

Registered 4 months after the study started (first participant enrolled Feb 2009, registered Jun 2009).

Phase: Phase 1/2
Study type: Interventional
Enrollment: 43
Allocation: Non-randomized
Ages: 18 Years to 70 Years
Sex: All

Study summary

Background:

The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with B cell lymphomas or leukemias that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patient s white blood cells with a retrovirus that has the gene for anti-cluster of differentiation 19 (CD19) incorporated in the retrovirus.

Objective:

The purpose of this study is to determine a safe number of these cells to infuse and to see if these particular tumor-fighting cells (anti-CD19 cells) cause tumors to shrink.

Eligibility:

Adults age 18-70 with B cell lymphomas or leukemias expressing the CD19 molecule.

Design:

Work up stage: Patients will be seen as an outpatient at the National Institutes of Health (NIH) clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed

Leukapheresis: If the patients meet all of the requirements for the study they will undergo leukapheresis to obtain white blood cells to make the anti-CD19 cells. Leukapheresis is a common procedure, which removes only the white blood cells from the patient.

Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy and the anti-CD19 cells. They will stay in the hospital for about 4 weeks for the treatment.

Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days.

Read the detailed description

BACKGROUND:

We have constructed a retroviral vector that encodes an anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) that recognizes the CD19 antigen. This chimeric receptor also contains the signaling domains of cluster of differentiation 28 (CD28) and cluster of differentiation 3 (CD3)-zeta. The retroviral vector can be used to mediate genetic transfer of this CAR to T cells with high efficiency (> 50%) without the need to perform any selection.
In co-cultures with CD19-expressing target cells, anti-CD19-CAR-transduced T-cells secreted significant amounts of interferon gamma (IFN-y) and interleukin 2 (IL-2).
We have developed a process for cryopreserving the cell product which may lead to the ability for this product to be manufactured at a central location and shipped to other institutions for treatment of a broader patient population

OBJECTIVE:

Primary objective:

--With the approval of amendment S, to determine the safety and feasibility of the administration of cryopreserved anti-CD19-CAR engineered peripheral blood lymphocytes with a non-myeloablative conditioning regimen in patients with Bcell lymphomas.

ELIGIBILITY:

Patients of 18 years of age or older must:

Have a CD19-expressing B-cell lymphoma
Be a non-responder to, or recurred after one or more standard chemotherapy-containing regimens for their malignancy
Currently require treatment due to progressive malignancy
Be deemed to be incurable by standard therapy

Patients may not have:

A history of allogeneic stem cell transplantation
Central nervous system (CNS) disease

DESIGN:

Peripheral blood mononuclear cells (PBMC) obtained by leukapheresis (approximately 5.0x 10\^9 cells) will be cultured in the presence of anti-CD3 (muromonab-CD3 (OKT3)) and aldesleukin in order to stimulate T-cell proliferation.
Transduction is initiated by exposure of approximately 1.0x 10\^8 to 5.0x 10\^8 cells to retroviral vector supernatant containing the anti-CD19 CAR.
With the approval of Amendment S, patients will receive fludarabine and cyclophosphamide chemotherapy (NMA) for lymphodepletion, followed by cryopreserved anti-CD19-CAR-transduced T-cells.
Patients will be followed until disease progression.
Patients who have responded to treatment and then progress may receive one retreatment.

Conditions studied

Primary Mediastinal B-cell Lymphoma
Diffuse, Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Mantle Cell

Browse trials for

Keywords

B Cell Malignancies
T Cell Persistence
Immunotherapy
Cell Transfer
Leukemia
Chronic Lymphocytic Leukemia
CLL
Lymphoma

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's enrollment of 43 is close to the median of 40 across 4,508 interventional studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 70 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Patient must have a cluster of differentiation 19 (CD19)-expressing B-cell lymphoma. Patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and diffuse large B-cell lymphoma transformed from follicular lymphoma must have measurable disease after at least two prior chemotherapy regimens one of which must have contained doxorubicin and rituximab.
1. Confirmation of diagnosis of B-cell malignancy and positivity for CD19 confirmed by the Laboratory of Pathology of the National Cancer Institute (NCI). The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patient. Immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood, fine needle aspirates and bone marrow samples.
2. Patients must have indications for treatment for their B-cell malignancy at the time of enrollment on this trial.
3. Greater than or equal to 18 years of age and less than or equal to age 70.
4. Willing to sign a durable power of attorney.
5. Able to understand and sign the Informed Consent Document.
6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.
7. Life expectancy of greater than three months.
8. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment.
9. Women of child bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.
10. Serology:
  - Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune -competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.).
  - Seronegative for hepatitis B antigen and hepatitis C antibody unless antigen negative. If hepatitis C antibody test is positive. Then patients must be tested for the presence of antigen by reverse transcription-polymerase chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA) negative.
11. Hematology:
  - Absolute neutrophil count greater than or equal to 1000/mm\^3 without the support of filgrastim.
  - Platelet count greater than or equal to 50,000/mm\^3.
  - Hemoglobin greater than 8.0 g/dl.
  - Lymphocyte count less than or equal to 4,000/ mm\^3
12. Chemistry:
  - Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 5 times the upper limit of normal.
  - Serum creatinine less than or equal to 1.6 mg/dl
  - Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl
13. More than three weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patient toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).
14. Normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram.

Exclusion criteria

EXCLUSION CRITERIA:

Patients that require urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression.
Patients that have active hemolytic anemia.
Patients with active brain metastases, or with a history of any central nervous system (CNS) metastases or cerebrospinal fluid malignant cells.
Note: patients who are asymptomatic but are found to have malignant cells in the cerebrospinal fluid (CSF) on lumbar puncture prior to treatment will be considered eligible.
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.
Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
Concurrent systemic steroid therapy.
History of severe immediate hypersensitivity reaction to any of the agents used in this study.
History of allogeneic stem cell transplantation
Patients with cardiac atrial or cardiac ventricular lymphoma involvement.

Screening Evaluation:

Within 4 weeks prior to starting the chemotherapy regimen:

Complete history and physical examination, including, weight and vital signs, noting in detail the exact size and location of any lesions that exist. (Note: patient history may be obtained within 8 weeks.)
Chest x-ray
Electrocardiography (EKG)
Baseline computed tomography (CT) of the chest, abdomen and pelvis, positron emission tomography (PET) scan, and brain magnetic resonance imaging (MRI) to evaluate the status of disease. Additional scans and x-rays may be performed if clinically indicated based on patient signs and symptoms.
HIV antibody titer and Hepatitis B surface antigen (HbsAG) determination, and anti HCV, (Note: May be performed within 3 months of the chemotherapy start date).
Anti cytomegalovirus (CMV) antibody titer, herpes simplex virus (HSV) serology, and Epstein-Barr virus (EBV) panel (Note: patients who are known to be positive for any of the above do not need to be retested; may be performed within 3 months of chemotherapy start date)
Patients with a left ventricular ejection fraction (LVEF) of less than or equal to 55% will not proceed to treatment (Note: may be performed within 8 weeks of treatment).
Cluster of differentiation 19 (CD19) staining of malignant cells by immunohistochemistry or flow cytometry (testing is permitted to be conducted at any time prior to this point).
All patients must have a T cells, B cells, and natural killer cells (TBNK) for Peripheral blood cluster of differentiation 3 (CD3) count and CD19#.
Patients with a history of leptomeningeal disease, or signs/symptoms suggestive of leptomeningeal involvement, or with symptoms of central nervous system malignancy such as new onset severe headaches, neck stiffness, or any focal neurologic findings on physical exam will have lumbar puncture for examination of cerebral spinal fluid.
Patients may undergo lumbar puncture (LP) for flow cytometry of the CSF in order to assess the presence of CD19 positive lymphocytes for potential correlation with neurologic toxicity. Patients who have no neurologic symptoms at the time of LP will be eligible for enrollment regardless of the results of the flow cytometry.
Within 14 days prior to starting the chemotherapy regimen:
Chem 20: (Sodium (Na), Potassium (K), Chloride (Cl), Total carbon dioxide (CO2) (bicarbonate), Creatinine, Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium total (Mg), Inorganic Phosphorus, Alkaline Phosphatase, ALT/glutamic pyruvic transaminase (GPT), AST/glutamic oxaloacetic (GOT), Total Bilirubin, Direct Bilirubin, lactate hydrogenase (LD), Total Protein, Total creatine kinase (CK), Uric Acid)
Thyroid panel
Complete blood count (CBC) with differential and platelet count
Prothrombin time (PT)/partial thromboplastin time (PTT)
Urinalysis and culture, if indicated
Within 7 days prior to starting the chemotherapy regimen:
Beta-human chorionic gonadotropin (βHCG) pregnancy test (serum or urine) on all women of child-bearing potential
ECOG performance status of 0 or 1

Study design

Phase: Phase 1 / Phase 2
Primary purpose: Treatment
Allocation: Non-randomized
Intervention model: Sequential assignment
Masking: None (open label)
Enrollment: 43 participants (actual)

Study arms

Experimental
1x10^9-1x10^10+ high dose Interleukin-2
Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + cryopreserved anti-CD19-CAR PBL
Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Aldesleukin
Experimental
1x10^9-1x10^10 + high dose Retreat
Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Aldesleukin
Experimental
0.5x10^7 cells/kg
Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL
Experimental
2.5x10^6 cells/kg
Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL
Experimental
1.0x10^6 cells/kg
Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL
Experimental
1.0x10^6 cells/kg (Reduced chemo)
Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Fludarabine · Drug: Cyclophosphamide
Experimental
2.0x10^6 cells/kg (Reduced chemo)
Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Fludarabine · Drug: Cyclophosphamide
Experimental
6.0x10^6 cells/kg (Reduced chemo)
Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Fludarabine · Drug: Cyclophosphamide
Experimental
2.0x10^6 cells/kg (Moderate chemo)
Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Fludarabine · Drug: Cyclophosphamide
Experimental
2.0x10^6 cells/kg (9-12 days culture)
Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

DrugFludarabine
Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
Also known as: Fludara
DrugCyclophosphamide
Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
Also known as: Cytoxan
BiologicalAnti-cluster of differentiation 19 (CD19)-CAR PBL
Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL). Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes.
DrugAldesleukin
Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
Also known as: Interleukin-2, IL-2
DrugFludarabine
Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
Also known as: Fludara
DrugCyclophosphamide
Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
Also known as: Cytoxan

What researchers measure

Primary outcomes

Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma
Participants were assessed by the Response Criteria for Malignant Lymphoma. Complete Remission (CR) is complete disappearance of all detectable evidence of disease and disease-related symptoms if present before therapy. Partial Remission (PR) requires ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses; no increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease (PD) is defined by ≥50% increase from nadir in the sum of the products of at least two lymph nodes, or if a single node is involved at least a 50% increase in the product of the diameters of this one node; and appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Scans performed at 6 weeks, 12 weeks and every 3-6 months for approximately 2 years

Secondary outcomes

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0).
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 101 months and 17 days.

Results

Posted Mar 21, 2019

Participant flow

Dose Administration

Participant flow — Dose Administration
Milestone	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)
Started	8	2	5	6	7	10	1	2	2
Completed	8	2	5	6	7	10	1	2	2
Not completed	0	0	0	0	0	0	0	0	0

1x10^9-1x10^10 + High Dose Retreat

Participant flow — 1x10^9-1x10^10 + High Dose Retreat
Milestone	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)
Started	3	0	0	0	0	0	0	0	0
Completed	3	0	0	0	0	0	0	0	0
Not completed	0	0	0	0	0	0	0	0	0

Outcome measures

PrimaryNumber of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma

Participants were assessed by the Response Criteria for Malignant Lymphoma. Complete Remission (CR) is complete disappearance of all detectable evidence of disease and disease-related symptoms if present before therapy. Partial Remission (PR) requires ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses; no increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease (PD) is defined by ≥50% increase from nadir in the sum of the products of at least two lymph nodes, or if a single node is involved at least a 50% increase in the product of the diameters of this one node; and appearance of a new lesion greater than 1.5 cm in any axis even if other lesions are decreasing in size. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:: Scans performed at 6 weeks, 12 weeks and every 3-6 months for approximately 2 years
Reported as:: Count of participants · Participants

Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma
Participants	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2 Retreat	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)
Complete Remission	2	3	2	3	3	2	6	0	2	2
Partial Remission	4	0	0	0	2	3	1	0	0	0
Stable Disease	1	0	0	0	0	0	1	0	0	0
Progressive Disease	0	0	0	1	0	2	2	1	0	0
Not Evaluable	1	0	0	1	1	0	0	0	0	0

SecondaryNumber of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0).

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:: Date treatment consent signed to date off study, approximately 101 months and 17 days.
Reported as:: Count of participants · Participants

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0).
Participants	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2 Retreat	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)
Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0).	8	1	2	5	6	7	10	1	2	2

Adverse events

Collected over Date treatment consent signed to date off study, approximately 101 months and 17 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	1/8 (12.5%)	7/8 (87.5%)	8/8 (100%)
1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2 Retreat	0/3 (0%)	1/3 (33.3%)	3/3 (100%)
0.5x10^7 Cells/kg	0/2 (0%)	2/2 (100%)	2/2 (100%)
2.5x10^6 Cells/kg	1/5 (20%)	3/5 (60%)	5/5 (100%)
1.0x10^6 Cells/kg	0/6 (0%)	2/6 (33.3%)	6/6 (100%)
1.0x10^6 Cells/kg (Reduced Chemo)	0/7 (0%)	2/7 (28.6%)	7/7 (100%)
2.0x10^6 Cells/kg (Reduced Chemo)	0/10 (0%)	7/10 (70%)	10/10 (100%)
6.0x10^6 Cells/kg (Reduced Chemo)	0/1 (0%)	1/1 (100%)	1/1 (100%)
2.0x10^6 Cells/kg (Moderate Chemo)	0/2 (0%)	2/2 (100%)	2/2 (100%)
2.0x10^6 Cells/kg (9-12 Days Culture)	0/2 (0%)	2/2 (100%)	2/2 (100%)

Most frequent serious events

Showing 10 of 41

Most frequent serious events
Event	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2 Retreat	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)General disorders	1/8	0/3	0/2	0/5	0/6	0/7	0/10	0/1	2/2	0/2
HypoxiaRespiratory, thoracic and mediastinal disorders	1/8	0/3	0/2	1/5	0/6	0/7	0/10	1/1	0/2	1/2
Somnolence/depressed level of consciousnessNervous system disorders	2/8	0/3	0/2	1/5	0/6	0/7	4/10	0/1	0/2	2/2
ConfusionNervous system disorders	0/8	0/3	2/2	0/5	0/6	0/7	3/10	1/1	2/2	2/2
Speech impairment (e.g., dysphasia or aphasia)Nervous system disorders	0/8	0/3	0/2	1/5	1/6	0/7	6/10	0/1	2/2	2/2
Dyspnea (shortness of breath)Respiratory, thoracic and mediastinal disorders	0/8	0/3	0/2	0/5	0/6	0/7	0/10	1/1	0/2	1/2
Febrile neutropeniaInfections and infestations	1/8	0/3	0/2	0/5	0/6	0/7	4/10	0/1	0/2	1/2
HypotensionCardiac disorders	0/8	0/3	1/2	1/5	0/6	0/7	2/10	0/1	1/2	0/2
Neuropathy: cranial::CN VII Motor-face; Sensory-tasteNervous system disorders	0/8	0/3	1/2	0/5	0/6	0/7	0/10	0/1	0/2	0/2
Ataxia (incoordination)Nervous system disorders	0/8	0/3	0/2	0/5	0/6	0/7	1/10	0/1	1/2	0/2

Most frequent other events

Showing 10 of 76

Most frequent other events
Event	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2 Retreat	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)
Febrile neutropeniaInfections and infestations	3/8	2/3	2/2	5/5	4/6	4/7	1/10	0/1	0/2	1/2
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)General disorders	1/8	1/3	0/2	0/5	1/6	3/7	6/10	1/1	0/2	0/2
HemoglobinBlood and lymphatic system disorders	6/8	2/3	1/2	4/5	3/6	3/7	8/10	1/1	1/2	2/2
Leukocytes (total WBC)Blood and lymphatic system disorders	8/8	3/3	2/2	5/5	6/6	5/7	0/10	0/1	0/2	0/2
LymphopeniaBlood and lymphatic system disorders	8/8	3/3	2/2	5/5	6/6	7/7	10/10	1/1	1/2	2/2
Neuropathy: motorNervous system disorders	0/8	0/3	0/2	0/5	1/6	0/7	3/10	1/1	0/2	0/2
Neutrophils/granulocytes (ANC/AGC)Blood and lymphatic system disorders	8/8	3/3	2/2	5/5	5/6	7/7	9/10	0/1	1/2	2/2
Pain::Head/headacheNervous system disorders	1/8	2/3	2/2	1/5	1/6	0/7	0/10	0/1	1/2	0/2
PlateletsBlood and lymphatic system disorders	8/8	3/3	2/2	5/5	4/6	1/7	1/10	0/1	1/2	1/2
TremorNervous system disorders	0/8	0/3	0/2	0/5	0/6	0/7	6/10	1/1	0/2	0/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)	Total
<=18 years	0	0	0	0	0	0	0	0	0	0
Between 18 and 65 years	8	2	5	5	5	8	1	2	1	37
>=65 years	0	0	0	1	2	2	0	0	1	6

Age, Continuous
Age, Continuous(years)	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)	Total
Mean	55.5 ± 5.7	52.0 ± 12.7	40.4 ± 6.8	58.0 ± 8.6	55.0 ± 13.7	52.1 ± 15.2	40.0	51.5 ± 2.1	58.5 ± 10.6	52.7 ± 11.5

Sex: Female, Male
Sex: Female, Male(Participants)	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)	Total
Female	0	1	2	4	0	2	0	0	1	10
Male	8	1	3	2	7	8	1	2	1	33

Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)	Total
Hispanic or Latino	0	0	1	0	0	1	0	0	0	2
Not Hispanic or Latino	8	2	4	6	7	9	1	2	2	41
Unknown or Not Reported	0	0	0	0	0	0	0	0	0	0

Race (NIH/OMB)
Race (NIH/OMB)(Participants)	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)	Total
American Indian or Alaska Native	0	0	0	1	0	0	0	0	0	1
Asian	0	0	0	0	0	0	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0	0	0
Black or African American	0	0	1	0	0	0	0	0	0	1
White	8	2	4	5	6	10	1	2	2	40
More than one race	0	0	0	0	0	0	0	0	0	0
Unknown or Not Reported	0	0	0	0	1	0	0	0	0	1

Region of Enrollment
Region of Enrollment(Participants)	1x10^9-1x10^10 Cells/kg + High-dose Interleukin-2	0.5x10^7 Cells/kg	2.5x10^6 Cells/kg	1.0x10^6 Cells/kg	1.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Reduced Chemo)	6.0x10^6 Cells/kg (Reduced Chemo)	2.0x10^6 Cells/kg (Moderate Chemo)	2.0x10^6 Cells/kg (9-12 Days Culture)	Total
United States	8	2	5	6	7	10	1	2	2	43

Study locations

1 site

National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland 20892, United States

References and documents

Publications

Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. PubMed 23546520 ↗
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20. PubMed 24055823 ↗
James N. Kochenderfer, M.D., Mark E. Dudley, Ph.D., Sadik H. Kassim, Ph.D., Robert O. Carpenter, James C. Yang, MD, Giao Q. Phan, MD, Marybeth S. Hughes, MD, Richard M. Sherry, MD, Steven Feldman, Ph.D., David Spaner, MD, PhD, Debbie-Ann N. Nathan, RN, Kathleen E. Morton, RN, Mary Ann Toomey, RN, and Steven A. Rosenberg, M.D., Ph.D. Effective Treatment of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma with Autologous T Cells Genetically-Engineered to Express an Anti-CD19 Chimeric Antigen Receptor. Oral Abstract Presentation 12-8-13 in New Orleans, LA at the American Society of Hematology annual meeting. Blood Annual Meeting abstract 2013. 122:168.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25. PubMed 25154820 ↗
Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024. Epub 2017 Mar 14. PubMed 28291388 ↗
James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter, Sadik H. Kassim, Jeremy J. Rose, William G. Telford, Frances T. Hakim, David C. Halverson, Daniel H. Fowler, Nancy M. Hardy, Anthony R. Mato, Dennis D. Hickstein, Juan C. Gea-Banacloche, Steven Z. Pavletic, Claude Sportes, Irina Maric, Steven A. Feldman, Brenna G. Hansen, Jennifer S. Wilder, Bazetta Blacklock-Schuver, Bipulendu Jena, Michael R. Bishop, Steven A. Rosenberg*, Ronald E. Gress* (co-senior authors). Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Oral Abstract Presentation 12-8-13 in New Orleans, LA at the American Society of Hematology annual meeting. Blood Annual Meeting abstracts 2013. 122:151.
Kochenderfer, J.N., Somerville, R., Lu, T., Shi, V., Yang, J.C., Sherry, R., Klebanoff, C., Kammula, U.S., Goff, S.L., Bot, A., Rossi, J., Sherman, M., Perez, A., Xue, A., Feldman, T.A., Friedberg, J.W., Roschewski, M.J., Feldman, S., McIntyre, L., Rosenberg, S.A. Anti-CD19 Chimeric Antigen Receptor T cells Preceded by Low-Dose Chemotherapy to Induce Remissions of Advanced Lymphoma. 2016 ASCO Annual Meeting. J Clin Oncol 34, 2016 (suppl; abstr LBA3010).
Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, McIntyre L, Bot A, Rossi J, Lam N, Rosenberg SA. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017 Oct 4;25(10):2245-2253. doi: 10.1016/j.ymthe.2017.07.004. Epub 2017 Jul 13. PubMed 28803861 ↗
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗
Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, Rosenberg SA, Kochenderfer JN. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020 Nov 10;38(32):3805-3815. doi: 10.1200/JCO.20.01467. Epub 2020 Oct 6. PubMed 33021872 ↗
Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, Bot A. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018 Aug 23;132(8):804-814. doi: 10.1182/blood-2018-01-828343. Epub 2018 Jun 12. PubMed 29895668 ↗
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8. PubMed 22160384 ↗
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28. PubMed 20668228 ↗

Study documents

Protocol and statistical analysis plan · Aug 23, 2018
Informed consent form · Jun 24, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00924326
Lead sponsor: National Cancer Institute (NCI)
Responsible party: Steven Rosenberg, M.D. (Principal Investigator, National Cancer Institute (NCI)) — Principal investigator
First posted: Jun 18, 2009
Start date: Feb 17, 2009
Primary completion: Sep 30, 2015
Completion: Nov 17, 2021
Results posted: Mar 21, 2019
Last update: Jan 12, 2022

Study contacts

Steven A Rosenberg, M.D., Ph.D.

principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma→

Other studies from this sponsor

National Cancer Institute (NCI)

Start the discussion